{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:54:35Z","timestamp":1793390075810,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.clim.2007.08.012","type":"journal-article","created":{"date-parts":[[2007,10,5]],"date-time":"2007-10-05T07:12:24Z","timestamp":1191568344000},"page":"13-30","source":"Crossref","is-referenced-by-count":195,"title":["TNF\u03b1 blockade in human diseases: An overview of efficacy and safety"],"prefix":"10.1016","volume":"126","author":[{"given":"Jan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ziring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maida","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Korin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gjertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Raj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2007.08.012_bib1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.1780270805","article-title":"Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years","volume":"27","author":"Pincus","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-199039010-00003","article-title":"Rational use of disease-modifying antirheumatic drugs","volume":"39","author":"Furst","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2007.08.012_bib3","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2007.08.012_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.1780340908","article-title":"Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage\u2013pannus junction in patients with rheumatoid arthritis","volume":"34","author":"Chu","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.08.012_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib16","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib19","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2007.08.012_bib20","doi-asserted-by":"crossref","first-page":"ii78","DOI":"10.1136\/ard.2004.034157","article-title":"Psoriatic arthritis treatment: biological response modifiers","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib23","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.bor.0000159926.42761.dd","article-title":"Treatment update on spondyloarthropathy","volume":"17","author":"Anandarajah","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib27","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2007.08.012_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib33","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib34","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib35","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib36","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2007.08.012_bib37","first-page":"510","article-title":"Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis","volume":"34","author":"Baraliakos","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib38","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/rheumatology\/41.2.228","article-title":"Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis","volume":"41","author":"Ten","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2007.08.012_bib42","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib43","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis","volume":"32","author":"Kimura","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib44","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/01.bor.0000169363.69066.d0","article-title":"Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis","volume":"17","author":"Adams","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn\u2019s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2007.08.012_bib47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2007.08.012_bib49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.mpg.0000182004.06031.ce","article-title":"A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn\u2019s disease (Abstract)","volume":"41","author":"Hyams","year":"2005","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.clim.2007.08.012_bib51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOG.0b013e32815b601b","article-title":"Biological therapies in inflammatory bowel disease: top\u2013down or bottom\u2013up?","volume":"23","author":"Oldenburg","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.clim.2007.08.012_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn\u2019s disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.clim.2007.08.012_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohn\u2019s disease patients with an attenuated response to infliximab","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2007.08.012_bib55","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.14309\/00000434-200509001-00843","article-title":"Maintenance of remission over 1 year in patients with active Crohn\u2019s disease treated with adalimumab: results of a blinded, placebo-controlled trial [abstract]","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2007.08.012_bib56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2007.08.012_bib57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","article-title":"Guideline for anti-TNF-alpha therapy in psoriatic arthritis","volume":"44","author":"Kyle","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2007.08.012_bib58","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn\u2019s disease: a user\u2019s guide for clinicians","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2007.08.012_bib59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib60","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib62","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1468-3083.2006.01707.x","article-title":"Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus","volume":"20","author":"Boehncke","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2007.08.012_bib63","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10227-005-0110-7","article-title":"Off-label dermatologic uses of anti-TNF-a therapies","volume":"9","author":"Alexis","year":"2005","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.clim.2007.08.012_bib64","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.clim.2007.08.012_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.all.0000199798.10047.74","article-title":"Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma","volume":"6","author":"Cazzola","year":"2006","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2007.08.012_bib66","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.rmed.2005.02.031","article-title":"Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation","volume":"99","author":"Rouhani","year":"2005","journal-title":"Respir. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(03)00010-8","article-title":"Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy","volume":"210","author":"Chin","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2007.08.012_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2007.08.012_bib70","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2007.08.012_bib71","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of Etanercept and Infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clim.2007.08.012_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajh.20752","article-title":"Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Busca","year":"2007","journal-title":"Am. J. Hematol."},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2007.08.012_bib73","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2006.061937","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006","volume":"65","author":"Furst","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib74","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib75","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2007.08.012_bib76","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2007.08.012_bib77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.clim.2007.08.012_bib78","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2007.08.012_bib79","first-page":"340","article-title":"The risk of serious infections is higher in daily practice than in clinical trials for RA patients recieving TNF blockers: a systematic retrospective study of 707 patients","volume":"52","author":"Salliot","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib80","first-page":"S548","article-title":"Serious infections in patients with rheumatoid arthritis who participated in adalimumab clinical trials","volume":"52","author":"Kent","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib81","first-page":"S738","article-title":"The incidence of serious infections is not increased in patients with rheumatoid arthritis treated with anti-TNF drugs compared to those treated with traditional DMARDs: results from anational prospective study","volume":"52","author":"Dixon","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib82","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2007.08.012_bib83","first-page":"S547","article-title":"Rheumatoid arthritis patients on TNF blockers have higher rates of infections","volume":"52","author":"Maury","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib84","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib85","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"Aids"},{"key":"10.1016\/j.clim.2007.08.012_bib86","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","article-title":"Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab","volume":"150","author":"Bartke","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib87","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib89","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib90","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.clim.2007.08.012_bib91","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib92","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib93","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib94","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib95","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib96","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(06)68579-6","article-title":"Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study","volume":"367","author":"Ferrara","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib97","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2007.08.012_bib98","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib99","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib100","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib101","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib102","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib103","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener\u2019s Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbspin.2004.03.003","article-title":"Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate","volume":"72","author":"Sellam","year":"2005","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.clim.2007.08.012_bib106","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib107","first-page":"S348","article-title":"Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis","volume":"52","author":"Klareskog","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib108","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib109","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2007.08.012_bib110","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2003.018093","article-title":"Treatment with TNF alpha antagonists in patients with rheumatoid arthritis induces anti-cardiolipin antibodies","volume":"63","author":"Jonsdottir","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.08.012_bib111","first-page":"756","article-title":"Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab","volume":"22","author":"Allanore","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib112","first-page":"S543","article-title":"Development of antibodies against infliximab treatment in rheumatoid arthritis: relation to infusion reactions and treatment response","volume":"52","author":"kapetanovic","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib113","first-page":"S560","article-title":"Incidence of human anti-humanized antibodies (HAHAs) to adalimumab in relationship to clinical response in patients with rheumatoid arthritis","volume":"52","author":"Bartelds","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib114","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents","volume":"31","author":"Mohan","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2007.08.012_bib115","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/art.22027","article-title":"Are we coming to terms with tumor necrosis factor inhibition in pregnancy?","volume":"54","author":"Salmon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib116","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2007.08.012_bib117","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.22028","article-title":"Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib118","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.08.012_bib119","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.08.012_bib120","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.08.012_bib121","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib122","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.clim.2007.08.012_bib124","first-page":"e1","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.08.012_bib125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","article-title":"Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial","volume":"18","author":"Shikiar","year":"2007","journal-title":"J. Derm. Treat."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661607013265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661607013265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T05:21:42Z","timestamp":1708233702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661607013265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1521661607013265"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2007.08.012","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}